In This Issue

• From the IASLC Tobacco Control Committee
• Prof. Juan Rosai: In Memoriam (1940–2020)

Editorials

• Filtering Data About Treatment-Induced Renal Injury: From Biology to Practice
• Current Understanding and Biomarker Application of Programmed Death-Ligand 1 Expression in Tumors
• Adverse Event Reporting at Professional Conferences: We Need Better Standards and Bigger Posters
• Circulating Cancer-Associated Cells for the Early Detection and Decision-Making Concerning Effective Therapeutic Strategies for NSCLC
• Molecular Testing in Lung Cancer: Still Big Gap in Implementation for Real-World Use

Editorial - Lung Cancer Worldwide

• Lung Cancer in Lithuania

Special Article

• Statistics in Oncology Series: Clinical Versus Statistical Significance in Studies of Thoracic Malignancies 

Review Article

• The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee

Original Articles

• Variation in Toxicity Reporting Methods for Early Phase Lung Cancer Treatment Trials at Oncology Conferences
• The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer
• Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC
• Circulating Giant Tumor-Macrophage Fusion Cells Are Independent Prognosticators in Patients With NSCLC
• Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC
• An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC
• Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC
• Harnessing Natural Killer Immunity in Metastatic SCLC
• Role of mTOR As an Essential Kinase in SCLC

Brief Report

• Comparison of Three Sequencing Panels Used for the Assessment of Tumor Mutational Burden in NSCLC Reveals Low Comparability

Image of the Month

• Squamous Cell Carcinoma of the Lung With Micropapillary Pattern

Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.

Authors are also welcome to submit to the journal's open access companion title, JTO Clinical and Research Reports, which welcomes a range of manuscripts from subset analyses of published trials to high-quality case reports